t2154 cat 133407 82 6 Search Results


mg 132  (TargetMol)
96
TargetMol mg 132
A Immunoblotting for MAGL expression in X01 GSCs after 24 h treatment with the indicated concentrations of JZL184 or JN-PROTAC. α-tubulin was used as a loading control. B Immunoblotting for MAGL expression in X01 GSCs treated with 0.5 μM of JN-PROTAC for the indicated durations. C Immunoblotting for MAGL expression in 528 GSCs after 24 h treatment with the indicated concentrations of JZL184 or JN-PROTAC. D , E Immunoblotting for MAGL expression in human breast tumor MDA-MB-231 cells ( D ) and murine melanoma B16F10 cells ( E ) after 24 h treatment with the indicated concentrations of JN-PROTAC. F Immunoblotting for MAGL expression in X01 GSCs after 24 h treatment with 500 nM of JN-PROTAC, 10 μM of TAK-243 or 10 μM of <t>MG-132.</t> TAK-243 and MG-132 are UBA1 inhibitor and proteasome inhibitor, respectively. G Immunoblotting for P53 and MAGL expression in X01 cells after 24 h treatment with the indicated concentrations of JN-PROTAC. H Co-IP assay for the PROTAC-induced ternary complex formation in X01 GSCs treated with JN-PROTAC (10 μM) or DMSO for 48 h. Cell lysates were precipitated with anti-MDM2 antibody. Vinculin was used as a loading control. I Co-IP assay for the interaction of MDM2 and P53 in X01 GSCs treated with JN-PROTAC (10 μM) or DMSO for 48 h. Cell lysates were precipitated with anti-MDM2 antibody. Vinculin was used as a loading control. J The proposed dual functional role of the JN-PROTAC in MAGL degradation and activation of tumor suppressor P53 through MDM2 blocking.
Mg 132, supplied by TargetMol, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mg 132/product/TargetMol
Average 96 stars, based on 1 article reviews
mg 132 - by Bioz Stars, 2026-04
96/100 stars
  Buy from Supplier
c1022 mitotracker deep red fm yeasen  (Beyotime)
99
Beyotime c1022 mitotracker deep red fm yeasen
A Immunoblotting for MAGL expression in X01 GSCs after 24 h treatment with the indicated concentrations of JZL184 or JN-PROTAC. α-tubulin was used as a loading control. B Immunoblotting for MAGL expression in X01 GSCs treated with 0.5 μM of JN-PROTAC for the indicated durations. C Immunoblotting for MAGL expression in 528 GSCs after 24 h treatment with the indicated concentrations of JZL184 or JN-PROTAC. D , E Immunoblotting for MAGL expression in human breast tumor MDA-MB-231 cells ( D ) and murine melanoma B16F10 cells ( E ) after 24 h treatment with the indicated concentrations of JN-PROTAC. F Immunoblotting for MAGL expression in X01 GSCs after 24 h treatment with 500 nM of JN-PROTAC, 10 μM of TAK-243 or 10 μM of <t>MG-132.</t> TAK-243 and MG-132 are UBA1 inhibitor and proteasome inhibitor, respectively. G Immunoblotting for P53 and MAGL expression in X01 cells after 24 h treatment with the indicated concentrations of JN-PROTAC. H Co-IP assay for the PROTAC-induced ternary complex formation in X01 GSCs treated with JN-PROTAC (10 μM) or DMSO for 48 h. Cell lysates were precipitated with anti-MDM2 antibody. Vinculin was used as a loading control. I Co-IP assay for the interaction of MDM2 and P53 in X01 GSCs treated with JN-PROTAC (10 μM) or DMSO for 48 h. Cell lysates were precipitated with anti-MDM2 antibody. Vinculin was used as a loading control. J The proposed dual functional role of the JN-PROTAC in MAGL degradation and activation of tumor suppressor P53 through MDM2 blocking.
C1022 Mitotracker Deep Red Fm Yeasen, supplied by Beyotime, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/c1022 mitotracker deep red fm yeasen/product/Beyotime
Average 99 stars, based on 1 article reviews
c1022 mitotracker deep red fm yeasen - by Bioz Stars, 2026-04
99/100 stars
  Buy from Supplier
hoechst 33342 beyotime  (Beyotime)
99
Beyotime hoechst 33342 beyotime
A Immunoblotting for MAGL expression in X01 GSCs after 24 h treatment with the indicated concentrations of JZL184 or JN-PROTAC. α-tubulin was used as a loading control. B Immunoblotting for MAGL expression in X01 GSCs treated with 0.5 μM of JN-PROTAC for the indicated durations. C Immunoblotting for MAGL expression in 528 GSCs after 24 h treatment with the indicated concentrations of JZL184 or JN-PROTAC. D , E Immunoblotting for MAGL expression in human breast tumor MDA-MB-231 cells ( D ) and murine melanoma B16F10 cells ( E ) after 24 h treatment with the indicated concentrations of JN-PROTAC. F Immunoblotting for MAGL expression in X01 GSCs after 24 h treatment with 500 nM of JN-PROTAC, 10 μM of TAK-243 or 10 μM of <t>MG-132.</t> TAK-243 and MG-132 are UBA1 inhibitor and proteasome inhibitor, respectively. G Immunoblotting for P53 and MAGL expression in X01 cells after 24 h treatment with the indicated concentrations of JN-PROTAC. H Co-IP assay for the PROTAC-induced ternary complex formation in X01 GSCs treated with JN-PROTAC (10 μM) or DMSO for 48 h. Cell lysates were precipitated with anti-MDM2 antibody. Vinculin was used as a loading control. I Co-IP assay for the interaction of MDM2 and P53 in X01 GSCs treated with JN-PROTAC (10 μM) or DMSO for 48 h. Cell lysates were precipitated with anti-MDM2 antibody. Vinculin was used as a loading control. J The proposed dual functional role of the JN-PROTAC in MAGL degradation and activation of tumor suppressor P53 through MDM2 blocking.
Hoechst 33342 Beyotime, supplied by Beyotime, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/hoechst 33342 beyotime/product/Beyotime
Average 99 stars, based on 1 article reviews
hoechst 33342 beyotime - by Bioz Stars, 2026-04
99/100 stars
  Buy from Supplier

Image Search Results


A Immunoblotting for MAGL expression in X01 GSCs after 24 h treatment with the indicated concentrations of JZL184 or JN-PROTAC. α-tubulin was used as a loading control. B Immunoblotting for MAGL expression in X01 GSCs treated with 0.5 μM of JN-PROTAC for the indicated durations. C Immunoblotting for MAGL expression in 528 GSCs after 24 h treatment with the indicated concentrations of JZL184 or JN-PROTAC. D , E Immunoblotting for MAGL expression in human breast tumor MDA-MB-231 cells ( D ) and murine melanoma B16F10 cells ( E ) after 24 h treatment with the indicated concentrations of JN-PROTAC. F Immunoblotting for MAGL expression in X01 GSCs after 24 h treatment with 500 nM of JN-PROTAC, 10 μM of TAK-243 or 10 μM of MG-132. TAK-243 and MG-132 are UBA1 inhibitor and proteasome inhibitor, respectively. G Immunoblotting for P53 and MAGL expression in X01 cells after 24 h treatment with the indicated concentrations of JN-PROTAC. H Co-IP assay for the PROTAC-induced ternary complex formation in X01 GSCs treated with JN-PROTAC (10 μM) or DMSO for 48 h. Cell lysates were precipitated with anti-MDM2 antibody. Vinculin was used as a loading control. I Co-IP assay for the interaction of MDM2 and P53 in X01 GSCs treated with JN-PROTAC (10 μM) or DMSO for 48 h. Cell lysates were precipitated with anti-MDM2 antibody. Vinculin was used as a loading control. J The proposed dual functional role of the JN-PROTAC in MAGL degradation and activation of tumor suppressor P53 through MDM2 blocking.

Journal: Cell Death Discovery

Article Title: MAGL targeted PROTAC degrader simultaneously enhances P53 for synergistic treatment of glioblastoma stem cell

doi: 10.1038/s41420-025-02392-1

Figure Lengend Snippet: A Immunoblotting for MAGL expression in X01 GSCs after 24 h treatment with the indicated concentrations of JZL184 or JN-PROTAC. α-tubulin was used as a loading control. B Immunoblotting for MAGL expression in X01 GSCs treated with 0.5 μM of JN-PROTAC for the indicated durations. C Immunoblotting for MAGL expression in 528 GSCs after 24 h treatment with the indicated concentrations of JZL184 or JN-PROTAC. D , E Immunoblotting for MAGL expression in human breast tumor MDA-MB-231 cells ( D ) and murine melanoma B16F10 cells ( E ) after 24 h treatment with the indicated concentrations of JN-PROTAC. F Immunoblotting for MAGL expression in X01 GSCs after 24 h treatment with 500 nM of JN-PROTAC, 10 μM of TAK-243 or 10 μM of MG-132. TAK-243 and MG-132 are UBA1 inhibitor and proteasome inhibitor, respectively. G Immunoblotting for P53 and MAGL expression in X01 cells after 24 h treatment with the indicated concentrations of JN-PROTAC. H Co-IP assay for the PROTAC-induced ternary complex formation in X01 GSCs treated with JN-PROTAC (10 μM) or DMSO for 48 h. Cell lysates were precipitated with anti-MDM2 antibody. Vinculin was used as a loading control. I Co-IP assay for the interaction of MDM2 and P53 in X01 GSCs treated with JN-PROTAC (10 μM) or DMSO for 48 h. Cell lysates were precipitated with anti-MDM2 antibody. Vinculin was used as a loading control. J The proposed dual functional role of the JN-PROTAC in MAGL degradation and activation of tumor suppressor P53 through MDM2 blocking.

Article Snippet: MG-132 (Cat. No. T2154), and TAK-243(Cat. No. T16974) were purchased from Shanghai Topscience Co., Ltd., and JZL184 (Cat. No. 3836) was received from Tocris Bioscience.

Techniques: Western Blot, Expressing, Control, Co-Immunoprecipitation Assay, Functional Assay, Activation Assay, Blocking Assay